Literature DB >> 26933792

Impact of multimodal therapy in locally recurrent rectal cancer.

Y N You1, J M Skibber1, C-Y Hu1, C H Crane2, P Das2, E S Kopetz3, C Eng3, B W Feig1, M A Rodriguez-Bigas1, G J Chang1.   

Abstract

BACKGROUND: The practice of salvaging recurrent rectal cancer has evolved. The aim of this study was to define the evolving salvage potential over time among patients with locally recurrent disease, and to identify durable determinants of long-term success.
METHODS: The study included consecutive patients with recurrent rectal cancer undergoing multimodal salvage with curative intent between 1988 and 2012. Predictors of long-term survival were defined by Cox regression analysis and compared over time. Re-recurrence and subsequent treatments were evaluated.
RESULTS: After multidisciplinary evaluation of 229 patients, salvage therapy with curative intent included preoperative chemotherapy and/or radiotherapy (73·4 per cent; with 41·3 per cent undergoing repeat pelvic irradiation), surgical salvage resection with or without intraoperative irradiation (36·2 per cent), followed by postoperative adjuvant chemotherapy (38·0 per cent). Multivisceral resection was undertaken in 47·2 per cent and bone resection in 29·7 per cent. The R0 resection rate was 80·3 per cent. After a median follow-up of 56·5 months, the 5-year overall survival rate was 50 per cent in 2005-2012, markedly increased from 32 per cent in 1988-1996 (P = 0·044). Long-term success was associated with R0 resection (P = 0·017) and lack of secondary failure (P = 0·003). Some 125 patients (54·6 per cent) developed further recurrence at a median of 19·4 months after salvage surgery. Repeat operative rescue was feasible in 21 of 48 patients with local re-recurrence alone and in 17 of 77 with distant re-recurrence, with a median survival of 19·8 months after further recurrence.
CONCLUSION: The long-term salvage potential for recurrent rectal cancer improved significantly over time, with the introduction of an individualized treatment algorithm of multimodal treatments and surgical salvage. Durable predictors of long-term success were R0 resection at salvage operation, avoidance of secondary failure, and feasibility of repeat rescue after re-recurrence.
© 2016 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 26933792      PMCID: PMC5407413          DOI: 10.1002/bjs.10079

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  35 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer.

Authors:  K Yamada; T Ishizawa; K Niwa; Y Chuman; S Akiba; T Aikou
Journal:  Br J Surg       Date:  2001-07       Impact factor: 6.939

Review 3.  Prognostic factors after surgery for locally recurrent rectal cancer: an overview.

Authors:  M Caricato; D Borzomati; F Ausania; S Valeri; A Rosignoli; R Coppola
Journal:  Eur J Surg Oncol       Date:  2005-12-27       Impact factor: 4.424

Review 4.  Surgery for recurrent rectal carcinoma: The role of preoperative magnetic resonance imaging.

Authors:  C Messiou; A Chalmers; K Boyle; P Sagar
Journal:  Clin Radiol       Date:  2006-03       Impact factor: 2.350

5.  Guideline for optimization of colorectal cancer surgery and pathology.

Authors:  Andrew J Smith; David K Driman; Karen Spithoff; Amber Hunter; Robin S McLeod; Marko Simunovic; Bernard Langer
Journal:  J Surg Oncol       Date:  2010-01-01       Impact factor: 3.454

6.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

7.  Outcomes of immediate vertical rectus abdominis myocutaneous flap reconstruction for irradiated abdominoperineal resection defects.

Authors:  Charles E Butler; A Ozlem Gündeslioglu; Miguel A Rodriguez-Bigas
Journal:  J Am Coll Surg       Date:  2008-02-11       Impact factor: 6.113

8.  Reconstruction of pelvic exenteration defects with anterolateral thigh-vastus lateralis muscle flaps.

Authors:  Sarah Wong; Patrick Garvey; John Skibber; Peirong Yu
Journal:  Plast Reconstr Surg       Date:  2009-10       Impact factor: 4.730

9.  Repeated resection of colorectal cancer pulmonary oligometastases: pooled analysis and prognostic assessment.

Authors:  Samer Salah; Kazuhiro Watanabe; Joon Suk Park; Alaa Addasi; Ji Won Park; Jon Zabaleta; Francesco Ardissone; Jhingook Kim; Marc Riquet; Kazunori Nojiri; Mara Gisabella; Sun Young Kim; Kuniya Tanaka
Journal:  Ann Surg Oncol       Date:  2013-01-20       Impact factor: 5.344

Review 10.  Resection of pulmonary metastases from colorectal carcinoma.

Authors:  R Warwick; R Page
Journal:  Eur J Surg Oncol       Date:  2007-11-26       Impact factor: 4.424

View more
  9 in total

Review 1.  Rectal Cancer in 2018: A Primer for the Gastroenterologist.

Authors:  Benjamin A Goldenberg; Emma B Holliday; Ramzi M Helewa; Harminder Singh
Journal:  Am J Gastroenterol       Date:  2018-12       Impact factor: 10.864

2.  Outcomes and prognostic factors of multimodality treatment for locally recurrent rectal cancer with curative intent.

Authors:  Thomas G Bird; Samuel Y Ngan; Julie Chu; René Kroon; Andrew C Lynch; Alexander G Heriot
Journal:  Int J Colorectal Dis       Date:  2018-02-21       Impact factor: 2.571

3.  Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.

Authors:  Naruhiko Ikoma; Y Nancy You; Brian K Bednarski; Miguel A Rodriguez-Bigas; Cathy Eng; Prajnan Das; Scott Kopetz; Craig Messick; John M Skibber; George J Chang
Journal:  J Clin Oncol       Date:  2017-06-28       Impact factor: 44.544

4.  Reevaluating the Evidence for Intensive Postoperative Extracolonic Surveillance for Nonmetastatic Colorectal Cancer.

Authors:  Jonah Popp; David S Weinberg; Eva Enns; John A Nyman; J Robert Beck; Karen M Kuntz
Journal:  Value Health       Date:  2021-10-13       Impact factor: 5.101

5.  Predictors of overall survival following extended radical resections for locally advanced and recurrent pelvic malignancies.

Authors:  Joseph C Kong; Oliver Peacock; Peadar S Waters; Tim Eglinton; Satish K Warrier; Christopher Wakeman; Frank A Frizelle; Alexander G Heriot; Jacob J McCormick
Journal:  Langenbecks Arch Surg       Date:  2020-06-12       Impact factor: 3.445

Review 6.  Pelvic exenteration for locally advanced and recurrent rectal cancer-how much more?

Authors:  Yee Chen Lau; Kilian G M Brown; Peter Lee
Journal:  J Gastrointest Oncol       Date:  2019-12

Review 7.  Contemporary Management of Locally Advanced and Recurrent Rectal Cancer: Views from the PelvEx Collaborative.

Authors: 
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.575

8.  Clinical Reality and Treatment for Local Recurrence of Rectal Cancer: A Single-Center Retrospective Study.

Authors:  Michał Jankowski; Manuela Las-Jankowska; Andrzej Rutkowski; Dariusz Bała; Dorian Wiśniewski; Karol Tkaczyński; Witold Kowalski; Iwona Głowacka-Mrotek; Wojciech Zegarski
Journal:  Medicina (Kaunas)       Date:  2021-03-19       Impact factor: 2.430

9.  Opportunities and Limitations of Pelvic Exenteration Surgery.

Authors:  Björn Lampe; Verónica Luengas-Würzinger; Jürgen Weitz; Stephan Roth; Friederike Rawert; Esther Schuler; Sabrina Classen-von Spee; Nando Fix; Saher Baransi; Anca Dizdar; Peter Mallmann; Klaus-Dieter Schaser; Andreas Bogner
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.